Chugai launches Vabysmo Intravitreal Injection in Japan

26 May 2022

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) announced that it launched anti VEGF/anti Ang-2 bispecific antibody Vabysmo Intravitreal Injection 120 g/mL (faricimab [genetical recombination]) for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization and diabetic macular edema (DME).

Vabysmo had been approved by the Ministry of Health, Labor and Welfare (MHLW) on March 28, and was listed on the national health insurance (NHI) reimbursement price list on Wednesday. Age-related macular degeneration associated with subfoveal choroidal neovascularization is generally known as neovascular age-related macular degeneration (nAMD).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK